Insurance for Life Sciences Companies:
From Pre-Clinical Through Commercialization

Product liability for life sciences companies extends far beyond traditional manufacturing exposures. For biotech and pharmaceutical companies, product liability coverage must address investigational compounds that have not yet received FDA approval, combination products, biosimilars, and cell and gene therapies with novel mechanisms of action. Standard commercial general liability policies are insufficient because they exclude or sublimit coverage for pharmaceutical and biotech products.

In the mid-Atlantic region, Pennsylvania's strict liability framework, New Jersey's Product Liability Act, Delaware's case law on design defect claims, and Maryland's contributory negligence standard each create distinct legal exposures for life sciences companies. A product liability program must account for these state-specific legal environments, especially for companies with operations, clinical sites, or distribution channels spanning multiple states.

Specialty life sciences product liability policies are written on either a claims-made or occurrence basis, with retroactive dates that align to the compound's first human exposure. We help structure programs that provide seamless coverage from preclinical toxicology studies through post-market surveillance, ensuring no gap exists as your compound moves through the development pipeline. Cross-links to our general liability coverage can supplement your program.

Contract Research Organizations and Contract Development & Manufacturing Organizations face professional liability exposures that are fundamentally different from their sponsor clients. When a CRO manages a clinical trial on behalf of a sponsor, errors in data collection, protocol adherence, regulatory filings, or adverse event reporting can lead to significant claims from the sponsor for financial losses, regulatory delays, or trial failure. Similarly, CDMOs face E&O claims when manufacturing deviations, out-of-specification results, or contamination events compromise a sponsor's product.

Professional liability / E&O coverage for CROs and CDMOs responds to allegations of negligent performance of contracted services, failure to meet cGMP or GLP standards, data integrity failures, regulatory submission errors, and breach of the master services agreement. Limits typically range from $1 million to $25 million depending on the organization's revenue, client base, and the value of the compounds they handle.

In Delaware and the broader mid-Atlantic corridor, the concentration of pharmaceutical and biotech companies creates strong demand for CRO and CDMO services, and with that demand comes heightened contractual liability requirements. Sponsors routinely require their contract partners to carry minimum E&O limits, name the sponsor as additional insured, and maintain coverage for extended reporting periods. We help CROs and CDMOs in DE, PA, NJ, MD & VA negotiate these requirements while securing coverage from carriers who understand the nuances of contract life sciences services. See also our professional liability page.

Life sciences companies are prime targets for cyberattacks because they hold extraordinarily valuable data: proprietary compound formulations, clinical trial data, patient health information (PHI), trade secrets, and intellectual property worth billions in future revenue. A ransomware attack on a CDMO's manufacturing execution system or a data breach exposing Phase III trial results can cause catastrophic financial and reputational damage.

Cyber liability insurance for life sciences companies covers first-party losses including business interruption from network security failures, data restoration costs, ransomware payments (where legally permissible), and notification expenses for breaches involving PHI or personally identifiable information under HIPAA, state breach notification laws in Delaware, Pennsylvania, New Jersey, Maryland, and Virginia, and the EU GDPR for companies conducting international trials.

Intellectual property insurance, while less common, is increasingly relevant for biotech startups and pharmaceutical companies facing patent infringement claims or needing to enforce their own patents. IP defense and pursuit coverage helps companies protect their innovations without depleting operating capital on litigation. We coordinate cyber and IP coverage with your broader life sciences program to eliminate gaps. Visit our cyber insurance page for additional details.

Life sciences companies operate in one of the most heavily regulated industries in the world. FDA inspections, Warning Letters, consent decrees, import alerts, and enforcement actions can result in significant financial penalties, product seizures, and injunctions that halt manufacturing or distribution. Regulatory compliance insurance, sometimes structured as a component of D&O or professional liability policies, covers defense costs and certain penalties arising from regulatory proceedings.

In the mid-Atlantic states, the FDA's Office of Regulatory Affairs maintains district offices that conduct inspections of manufacturing facilities, laboratories, and clinical sites in Delaware, Pennsylvania, New Jersey, Maryland, and Virginia. State-level regulatory bodies, including state pharmacy boards, departments of health, and environmental agencies, add additional compliance obligations. Companies that manufacture controlled substances face additional DEA oversight and state controlled substance regulations.

Our specialty carrier relationships include markets that offer regulatory defense coverage, recall expense coverage, and crisis management resources specifically designed for life sciences companies. These policies respond when an FDA 483 observation escalates to a Warning Letter, when a voluntary recall becomes necessary due to a manufacturing deviation, or when a state regulatory body initiates an investigation. We structure these coverages as part of an integrated program that protects your company at every regulatory touchpoint.

While clinical trial liability and product liability dominate life sciences insurance discussions, the foundational coverages of commercial general liability and property insurance remain essential. Laboratory facilities, cleanrooms, manufacturing suites, and office spaces all require property coverage for buildings, tenant improvements, business personal property, and specialized equipment such as bioreactors, HPLC systems, mass spectrometers, and cold storage units.

Business income and extra expense coverage protects against revenue loss when a covered peril, such as fire, water damage, or equipment breakdown, forces a suspension of operations. For life sciences companies, the cost of interrupted manufacturing runs, compromised stability studies, or delayed clinical trial timelines can far exceed the physical property damage itself. Equipment breakdown coverage, which responds to mechanical and electrical failure of critical laboratory and manufacturing equipment, is a crucial supplement.

Commercial general liability for life sciences companies covers premises liability for employees and visitors, completed operations for products that have entered the stream of commerce, and personal and advertising injury. We coordinate CGL coverage with your product liability and clinical trial liability programs to ensure there are no gaps or overlapping coverage disputes. For companies with vehicle fleets or employees who drive for business purposes, commercial auto insurance completes the liability program.